Market Overview

Brean Capital Says Regeneron Pharma Robust Pipeline Drives Upside, Calls Out Dupilumab As Next Catalyst

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for REGN

DateFirmActionFromTo
Dec 2016BMO CapitalInitiates Coverage OnMarket Perform
Dec 2016BTIG ResearchUpgradesNeutralBuy
Dec 2016Chardan CapitalUpgradesSellNeutral

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (REGN)